Taren Grom, Editor
NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
In today’s biopharma economy, declining R&D productivity combined with increased development costs have made investment portfolio managers skittish, says Chip Gillooly, VP, capital, at Quintiles. “The risks associated with investments are high, and the lack of output is making everyone nervous,” he says. “To manage this new high-risk environment, and continue to deliver valuable and accessible therapies, biopharma companies must find ways to increase output, decrease costs, and eliminate unnecessary layers of bureaucracy that hinder productivity. As new drug applications arising from discovery efforts have dried up, investors… Experts on this Topic Chip Gillooly, VP, capital, at Quintiles. James DeSanti, founder and CEO of PharmaVigilant Nagaraja Srivatsan, VP and head of life sciences, North America, Cognizant Kevin Hrusovsky, president and CEO of Caliper Life Sciences Robin Winter-Sperry, M.D., president and CEO, Scientific Advantage, and Science Oriented Solutions (SOS) Darshan Kulkarni, Pharm.D, Esq., principal attorney, Kulkarni Fran DeGrazio, VP, marketing and strategic business development, at West Pharmaceutical Services Mark Goldberg, M.D., chief operating officer, Parexel International Michael Parisi, president of Altum, part of CommonHealth Michael Naimoli, U.S. life sciences industry solutions director, Microsoft Scott Treiber, executive VP, clinical development solutions, inVentiv Clinical Solutions Jens Oliver Funk, M.D., senior VP and global head of TA oncology at EMD Serono Clare Colletti, inVentiv Advance Insights